Hypertrophic cardiomyopathy_HCM

Gene: TTN

Amber List (moderate evidence)

TTN (titin)
EnsemblGeneIds (GRCh38): ENSG00000155657
EnsemblGeneIds (GRCh37): ENSG00000155657
OMIM: 188840, Gene2Phenotype
TTN is in 14 panels

1 review

Dean Phelan (Victorian Clinical Genetics Services)

I don't know

ClinGen gene curation (2017):
The TTN gene has been associated with hypertrophic cardiomyopathy (HCM) in one family with an unusual presentation including variable dilatation, hypertrophy, and trabeculations with some family members meeting criteria for LVNC (Hastings et al, 2016, PMID 27625337). A heterozygous missense variant of unknown significance was reported in affected individuals in this family. Several other variants (missense, splice-site, in frame insertion) have been reported in TTN in patients with HCM. However, upon review, none of these variants were considered to have sufficient evidence to be disease-causing. The mechanism for disease is unknown. Experimental evidence to support the gene-disease association includes its biochemical function as a sarcomere component and protein interaction studies.
In summary, there is limited evidence to support this gene-disease association. Curation Expert Panel on December 14, 2017.

PMID: 28822653 (2017): Our study suggests that TTNtv might be a genetic modifier of HCM and confer an increased risk for cardiovascular death.

PMID: 28223422(2017): suggest oligogenic etiology.

PMID: 28323875 (2017): TTN mutations common in cohort of patients with severe right ventricular hypertrophy.

PMID: 28797094 (2017): deep intronic TTN variants enriched in patients with HCM

PMID: 31628103 (2019): screened HCM cohort (MURF1 binding domain only) and found two missense variants in two unrelated families. Variants segregated with disease (3 affected members of one family, 2 affected members of the other family). Variants are located in the MURF1 binding domain and in vitro functional studies showed increased binding to MURF1 (in vivo studies using zebrafish murf1 mutants show hypertrophic heart and disrupted sarcomeric structure). Suggested to be a novel (dominant negative) mechanism underlying HCM pathogenesis. (note: didn't find variants in GnomAD - quick search)

Summary: Insufficient evidence to support HCM gene-disease association
Created: 29 Jul 2020, 2:32 a.m. | Last Modified: 29 Jul 2020, 2:32 a.m.
Panel Version: 0.89

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Publications

History Filter Activity

29 Jul 2020, Gel status: 2

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: ttn has been classified as Amber List (Moderate Evidence).

29 Jul 2020, Gel status: 2

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Phenotypes for gene: TTN were changed from to Hypertrophic cardiomyopathy

29 Jul 2020, Gel status: 2

Set publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Publications for gene: TTN were set to

29 Jul 2020, Gel status: 2

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: ttn has been classified as Amber List (Moderate Evidence).

29 Jul 2020, Gel status: 3

Set mode of inheritance

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Mode of inheritance for gene: TTN was changed from Unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

17 Nov 2019, Gel status: 3

Created, Added New Source, Set mode of inheritance

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: TTN was added gene: TTN was added to Hypertrophic cardiomyopathy_VCGS. Sources: Expert Review Green,Victorian Clinical Genetics Services Mode of inheritance for gene: TTN was set to Unknown